Rznomics

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • USD 1,223,160 and AUD 11,595 accounts payable exposure as of FY2025 end, doubled USD payables from prior period
• • Derivative liabilities zero for FY2025, down from KRW 68.7B derivative liabilities at prior year-end

Management Discussion & Analysis

• • Revenue KRW 7.92B in 2025 from research collaboration and license fees with global pharma, operating loss KRW 14.6B, net loss KRW 103.8B
• • Largest revenue driver: research collaboration and license contracts generating KRW 7.92B, enabled by stable clinical trials of gene therapy RZ-001

Business Overview

• • Core business: RNA trans-splicing ribozyme platform for gene therapy and circular RNA platform, focused on oncology, rare diseases, degenerative diseases
• • 2025 KOSDAQ listing with IPO on Dec 18, 2025, net proceeds KRW 44.68B for operations and R&D

What are the latest Rznomics DART filings in 2026?

Rznomics (KRX code 476830) has filed an annual report on March 23, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Rznomics file its most recent annual report?

Rznomics filed its most recent annual report on March 23, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Rznomics's KRX stock code?

Rznomics's KRX stock code is 476830. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 476830 to look up all Rznomics disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Rznomics file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Rznomics.

Where can I find Rznomics financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Rznomics annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.